Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Chimeric antigen receptor (CAR)-T cell immunotherapy has considerably changed the landscape of treatment options for blood cancers. CAR-T therapy aims to redirect a patient’s T cells to recognize and ...
Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results